Search research articles
Contact Us
Filters
Showing results (61-70 of 103) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2021
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J Casak, Leigh Marcus, Lola Fashoyin-Aje, et al.
Plos Biology
|
August 8, 2008
TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation
Sejin Ahn, Gwanghee Lee, Soo Jung Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2017
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
Meredith K Chuk, Jennie T Chang, Marc R Theoret, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 6, 2004
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
Christopher A Klebanoff, Steven E Finkelstein, Deborah R Surman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
Ashley C Woods, E Dianne Pulte, Xin Wang, et al.
The Lancet. Oncology
|
January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
JHEP Reports : Innovation in Hepatology
|
May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma
David J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation
Ashley C Woods, Kelly J Norsworthy, Moran Choe, et al.
JAMA Oncology
|
December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
The Lancet. Oncology
|
December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 103) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2021
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J Casak, Leigh Marcus, Lola Fashoyin-Aje, et al.
Plos Biology
|
August 8, 2008
TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation
Sejin Ahn, Gwanghee Lee, Soo Jung Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2017
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
Meredith K Chuk, Jennie T Chang, Marc R Theoret, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 6, 2004
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
Christopher A Klebanoff, Steven E Finkelstein, Deborah R Surman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
Ashley C Woods, E Dianne Pulte, Xin Wang, et al.
The Lancet. Oncology
|
January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
JHEP Reports : Innovation in Hepatology
|
May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma
David J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation
Ashley C Woods, Kelly J Norsworthy, Moran Choe, et al.
JAMA Oncology
|
December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
The Lancet. Oncology
|
December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.
Page
of 11